The compound 3PO has been identified to be an inhibitor of PFKFB3 (19) and has been reported to attenuate glycolytic activity and attenuate tumor growth in bladder, liver, breast (11) and colon cancers (34). The gene discussed is PFKFB3; the disease is neoplasm.